Low Testosterone Treatment Lawsuit News: Investigation Reveals Testosterone Makers Fund Doctors’ Ed Courses on Testosterone Therapy

Print

Wright & Schulte LLC Is Representing Men In Low Testosterone Treatment Lawsuit Complaints That Allege Testosterone Makers Failed To Disclose Cardiovascular Risks Associated With Their Products.

Low-Testosterone-Drug-Lawsuits-Wright-and-Schulte-LLCLow Testosterone Treatment Lawsuit News: An investigative news report found that educational courses offered for doctors on testosterone medications, such as AndroGel and Depo Testosteone, downplay the risks of the drugs and lead to the overuse of testosterone in older men. News investigators also discovered testosterone manufacturers fund the medical courses, and influence doctors to prescribe the drug. In addition to facing criticism over funding courses, testosterone manufacturers are also defending themselves against low testosterone treatment lawsuit complaints filed on behalf of men who allege they suffered heart attack, blood clots, stroke, and cardiac death due to taking testosterone replacement therapy.

The Milwaukee Journal Sentinel/MedPage Today’s investigation showed the continuing education courses brought in a near-record income of $2.7 billion in 2014. Of that total, $676 million came from the drug and medical device industry. The investigators’ review of 75 courses funded by the testosterone industry showed that half the faculty had been paid by the companies as speakers, consultants and advisers. Additionally, in 65 of the 75 courses, at least one faculty member had worked for a company that either made or marketed testosterone products. Critics of testosterone makers question whether doctors are “getting unbiased information” about the drug, according to the investigation.
[jsonline.com/watchdog/watchdogreports/testosterone-courses-downplay-risks-lead-to-overuse-in-older-men-b99595151z1-333591801.html, Journal Sentinel, October 17, 2015.

“Low-T” medications such as AndroGel, Androderm and Axiron have been approved by the U.S. Food and Drug Administration (FDA) to treat hypogonadism, a condition occurring in men with low testosterone levels associated with a medical condition and not due to age. The investigative report mentioned data from IMS Health, a drug market research firm, that showed just under 1 million prescriptions were written for testosterone products in 2000. In 2014, the figure had climbed to 6.5 million, a sixfold increase over the past 15 years. In an article published the New England Journal of Medicine in August, the FDA stated that most men who take prescription testosterone products do not seem to have hypogonadism and this appears to be a troubling trend.

Testosterone products have also come under scrutiny by the FDA. In January 2014, the agency announced it was re-evaluating the safety and effectiveness of all FDA-approved testosterone products. In March, the FDA directed testosterone makes to update the safety labels of their products to include a warning about the possible increased risk of heart attacks and strokes. The regulatory agency also directed companies to warn that testosterone replacement therapy is not approved for men with low testosterone due to aging.
[fda.gov/Drugs/DrugSafety/ucm436259.htm, FDA, March 3, 2015]

After the FDA announced its probe of testosterone products, an industry-wide multidistrict litigation was created for lawsuits filed in federal courts accusing testosterone makers of failing to warn that their products carry the risk of heart attack, stroke, blood clots and cardiac death, according to court documents. All federally filed testosterone lawsuits are consolidated in the U.S. District Court, Northern District of Illinois where U.S. District Judge Matthew F. Kennelly is presiding over the coordinated pretrial proceedings.

Court documents show that testosterone makers involved in the multidistrict litigation are:

  • AbbVie and Abbot Laboratories, the makers and marketers of AndroGel
  • Actavis, Inc. and Watson Pharmaceuticals, which makes AndroDerm
  • Auxilium Pharmaceuticals, Inc., which makes Testim
  • Endo Pharmaceuticals Inc., which makes Delatestryl and Fortesta
  • Eli Lilly and Company and Lilly USA LLC, makers of Axiron
  • Pfizer Inc. and its subsidiary, Pharmacia & Upjohn Co.which makes and markets Depo-Testosterone

(In re: Testosterone Replacement Therapy ProductLiabilityLitigation –MDL No. 2545)

About Wright & Schulte LLC And Filing A Low Testosterone Therapy Lawsuit: Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright Schulte LLC stand up for the rights of people who have been injured or wronged, and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free testosterone lawsuit case evaluations are available through yourlegalhelp.com, or call 1-888-399-0795.

Contact:
Wright & Schulte LLC
865 S. Dixie Dr.
Vandalia, Ohio 45377
1-800-399-0795
http://www.yourlegalhelp.com

This entry was posted in Wright & Schulte Lawsuit News. Bookmark the permalink.